My Manhattan Institute colleagues James Copland and Paul Howard are the authors of a just-released paper which proposes comprehensive federal preemption of state product liability drug litigation, combined with a new administrative compensation program for persons injured by unforeseen drug side effects, modeled on the existing vaccine injury compensation program. Their paper is here, and the section on administered compensation begins here. A summary, and early reaction: Medical News Today, Legal NewsLine, their Washington Times op-ed, AmLaw Daily ("makes for interesting reading"), Drug and Device Law.
Copland and Howard: a proposal for drug-injury administrative compensation
Related Entries:
- Greg Conko: Can brand makers be sued for generic drug injuries?
- Greg Conko discusses the FDA's ban on off-label promotion
- November 23 roundup
- Around the web, August 26
- BREAKING: Bruesewitz v. Wyeth
- "The Whooping Cough's Unnecessary Return"
- Around the web, January 20
- Around the web, January 13
- British Medical Journal details Andrew Wakefield's vaccine/autism fraud
- Around the web, November 15
- Around the web, October 28
- "Are we headed back to the bad old days of vaccination lawsuits?"
- Around the web, October 16
- Amy Wallace on being sued by anti-vaccine activists
- Federal Circuit again rejects vaccine-autism junk science claims
![]() |
Rafael Mangual Project Manager, Legal Policy rmangual@manhattan-institute.org |
![]() |
Communications Manhattan Institute communications@manhattan-institute.org |